葛兰素史克Glaxosmithkline（GSK）2024年负责任商业绩效报告「LSE」（英文版）（54页）.pdf

1、1 GSK Responsible Business Performance Report 2024March 2025Responsible Business Performance Report 20242 GSK Responsible Business Performance Report 2024March 2025Our purpose is to unite science,technology and talent to get ahead of disease together.We aim to positively impact the health of 2.5 bil

2、lion people by the end of 2030,as a successful,growing company with strong momentum,where outstanding people can thrive.In this report:CEOs statement 3Our approach 4Our culture and people 9Progress in 2024 Our six focus areas Access 11Global health and health security 16Environment 19Inclusion and d

3、iversity 27Ethical standards 29Product governance 34Appendix People disclosures 37GRI and SASB index 39Independent Limited Assurance Reports 47Cautionary statementThis document may contain forward-looking statements.Forward-looking statements give the Groups current expectations or forecasts of futu

4、re events.An investor can identify these statements by the fact that they do not relate strictly to historical or current facts.They use words such as anticipate,believe,estimate,expect,intend,plan,project,target,will and other words and terms of similar meaning in connection with any discussion of

5、future operating or financial performance.In particular,these include statements relating to future actions,prospective products or product approvals,future performance or results of current and anticipated products,sales efforts,expenses,the outcome of contingencies such as legal proceedings,divide

6、nd payments and financial results.Other than in accordance with its legal or regulatory obligations(including under the Market Abuse Regulations,UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority),the Group undertakes no obligation to update any fo